Edesa Biotech (EDSA) Projected to Post Quarterly Earnings on Friday

Edesa Biotech (NASDAQ:EDSA) is expected to release its results before the market opens on Friday, February 13th. Analysts expect Edesa Biotech to post earnings of ($0.28) per share for the quarter.

Edesa Biotech (NASDAQ:EDSA) last released its quarterly earnings results on Friday, December 12th. The company reported $0.53 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.80. The firm had revenue of $0.25 million for the quarter. On average, analysts expect Edesa Biotech to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Edesa Biotech Stock Down 6.3%

Shares of EDSA stock opened at $1.05 on Wednesday. The business has a 50-day moving average price of $1.44 and a two-hundred day moving average price of $1.96. Edesa Biotech has a 12-month low of $0.94 and a 12-month high of $4.49. The firm has a market cap of $8.75 million, a P/E ratio of -0.78 and a beta of 0.21.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Edesa Biotech in a research note on Monday, December 29th. HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of Edesa Biotech in a report on Monday, November 3rd. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Edesa Biotech has an average rating of “Hold” and an average price target of $5.00.

Hedge Funds Weigh In On Edesa Biotech

An institutional investor recently bought a new position in Edesa Biotech stock. Susquehanna International Group LLP purchased a new stake in shares of Edesa Biotech, Inc. (NASDAQ:EDSA) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 14,610 shares of the company’s stock, valued at approximately $36,000. Susquehanna International Group LLP owned about 0.21% of Edesa Biotech at the end of the most recent reporting period. 5.50% of the stock is currently owned by hedge funds and other institutional investors.

About Edesa Biotech

Edesa Biotech, Inc is a clinical-stage biotechnology company focused on the discovery and development of next-generation vaccines and immunotherapies. The company leverages a proprietary self-amplifying RNA platform to create candidates designed for both intranasal and injectable administration. Edesa’s approach aims to elicit robust mucosal and systemic immune responses, with applications spanning infectious diseases and immuno-oncology.

Among Edesa’s pipeline programs is a lead intranasal vaccine candidate targeting SARS-CoV-2, currently advancing through early-stage clinical trials.